# Evotec SE (EVO)

Source: https://www.quantisnow.com/company/EVO
Generated: 2026-11-16T00:40:27.096Z

- Ticker: EVO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- SEC CIK: 0001412558
- Website: https://www.evotec.com

## About

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

## Latest EVO news and filings

- 2026-11-05 12:23 UTC [SEC Form 6-K] [SEC Form 6-K filed by Evotec SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-evotec-se-6774634)
- 2026-11-05 07:18 UTC [Earnings Date] [Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals](https://www.quantisnow.com/insight/evotec-reports-third-quarter-and-nine-month-2026-results-building-growth-6773924)
- 2026-10-29 07:00 UTC [Earnings Date] [Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026](https://www.quantisnow.com/insight/evotec-se-to-announce-results-for-the-first-nine-months-6761983)
- 2026-10-15 12:43 UTC [SEC Form 6-K] [SEC Form 6-K filed by Evotec SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-evotec-se-6747483)
- 2026-10-15 06:04 UTC [Leadership Update] [Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board](https://www.quantisnow.com/insight/evotec-appoints-dr-joanna-holbrook-as-chief-scientific-officer-and-6747048)
- 2026-10-14 10:02 UTC [SEC Form 6-K] [SEC Form 6-K filed by Evotec SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-evotec-se-6745751)
- 2026-09-29 10:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by Evotec SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-evotec-se-6728270)
- 2026-09-29 06:04 UTC [Evotec Announces Chief Scientific Officer Transition](https://www.quantisnow.com/insight/evotec-announces-chief-scientific-officer-transition-6728185)
- 2026-09-09 10:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by Evotec SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-evotec-se-6709057)
- 2026-09-09 06:00 UTC [Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies](https://www.quantisnow.com/insight/just---evotec-biologics-advances-us-department-of-war-antibodies-6708966)
- 2026-09-02 06:04 UTC [Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors](https://www.quantisnow.com/insight/evotec-and-plectonic-enter-research-collaboration-to-explore-new-generation-6702073)
- 2026-08-13 10:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by Evotec SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-evotec-se-6679030)
- 2026-08-06 06:16 UTC [Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases](https://www.quantisnow.com/insight/evotec-and-odyssey-therapeutics-enter-ai-enabled-rd-collaboration-in-autoimmune-6666713)
- 2026-08-03 12:32 UTC [Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168](https://www.quantisnow.com/insight/niagen-bioscience-selects-global-drug-development-pioneer-evotec-to-advance-6658893)
- 2026-07-23 07:00 UTC [Evotec Selects Navan to Unify Global Travel, Payments, and Expense Management](https://www.quantisnow.com/insight/evotec-selects-navan-to-unify-global-travel-payments-and-expense-6645905)
- 2026-07-16 12:46 UTC [Analyst Downgrade] [Evotec SE downgraded by Berenberg](https://www.quantisnow.com/insight/evotec-se-downgraded-by-berenberg-6639185)
- 2026-07-15 12:43 UTC [Analyst Downgrade] [Evotec SE downgraded by TD Cowen with a new price target](https://www.quantisnow.com/insight/evotec-se-downgraded-by-td-cowen-with-a-new-price-6637752)
- 2026-07-13 21:54 UTC [SEC Form 6-K] [SEC Form 6-K filed by Evotec SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-evotec-se-6635870)
- 2026-07-13 19:43 UTC [Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook](https://www.quantisnow.com/insight/ad-hoc-evotec-announces-preliminary-second-quarter-and-first-half-6635265)
- 2026-06-30 17:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by Evotec SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-evotec-se-6620510)
- 2026-06-30 06:16 UTC [Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics](https://www.quantisnow.com/insight/just---evotec-biologics-launches-jtrain-to-deliver-turnkey-continuous-6619701)
- 2026-06-17 10:02 UTC [SEC Form 6-K] [SEC Form 6-K filed by Evotec SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-evotec-se-6605749)
- 2026-06-11 16:02 UTC [Evotec Reports Results of the Annual General Meeting 2026](https://www.quantisnow.com/insight/evotec-reports-results-of-the-annual-general-meeting-2026-6598614)
- 2026-06-02 05:45 UTC [Market Insight] [Evotec Appoints Rui Wang as Head of Global In Silico and AI](https://www.quantisnow.com/insight/evotec-appoints-rui-wang-as-head-of-global-in-silico-6582846)
- 2026-05-12 21:15 UTC [Market Insight] [Evotec SE Successfully Placed €116.1 Million Convertible Bonds](https://www.quantisnow.com/insight/evotec-se-successfully-placed-1161-million-convertible-bonds-6548879)
- 2026-05-06 13:39 UTC [SEC Form 6-K] [SEC Form 6-K filed by Evotec SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-evotec-se-6534449)
- 2026-05-04 05:50 UTC [Market Insight] [Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall](https://www.quantisnow.com/insight/evotec-announces-nomination-of-first-preclinical-development-candidate-in-dermatology-6527732)
- 2026-04-30 15:48 UTC [SEC Form 6-K] [SEC Form 6-K filed by Evotec SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-evotec-se-6523521)
- 2026-04-30 07:20 UTC [Market Insight] [Evotec Receives Grants to Advance Tuberculosis Treatment](https://www.quantisnow.com/insight/evotec-receives-grants-to-advance-tuberculosis-treatment-6522248)
- 2026-04-29 20:45 UTC [Market Insight] [Evotec Announces New Nomination to Board of Directors](https://www.quantisnow.com/insight/evotec-announces-new-nomination-to-board-of-directors-6521777)
- 2026-04-29 05:50 UTC [Market Insight] [Evotec SE to Announce First Quarter 2026 Results on May 6, 2026](https://www.quantisnow.com/insight/evotec-se-to-announce-first-quarter-2026-results-on-may-6519662)
- 2026-04-24 10:03 UTC [SEC Form 6-K] [SEC Form 6-K filed by Evotec SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-evotec-se-6513445)
- 2026-04-24 05:50 UTC [Market Insight] [Evotec Announces Chief Financial Officer Transition](https://www.quantisnow.com/insight/evotec-announces-chief-financial-officer-transition-6513360)
- 2026-04-15 12:08 UTC [Analyst Coverage Resumed] [H.C. Wainwright resumed coverage on Evotec SE with a new price target](https://www.quantisnow.com/insight/hc-wainwright-resumed-coverage-on-evotec-se-with-a-new-6500605)
- 2026-04-15 05:50 UTC [Market Insight] [Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer](https://www.quantisnow.com/insight/evotec-appoints-dr-ingrid-mller-as-chief-operating-officer-6500219)
- 2026-04-08 15:56 UTC [SEC Form 6-K] [SEC Form 6-K filed by Evotec SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-evotec-se-6492605)
- 2026-04-08 15:52 UTC [SEC Form 20-F filed by Evotec SE](https://www.quantisnow.com/insight/sec-form-20-f-filed-by-evotec-se-6492601)
- 2026-04-07 16:44 UTC [SEC Form 6-K] [SEC Form 6-K filed by Evotec SE](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-evotec-se-6490929)
- 2026-04-07 07:00 UTC [Market Insight] [Evotec Nominates Dieter Weinand as Supervisory Board Chairman](https://www.quantisnow.com/insight/evotec-nominates-dieter-weinand-as-supervisory-board-chairman-6490076)
- 2026-04-01 09:35 UTC [Market Insight] [Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026](https://www.quantisnow.com/insight/evotec-se-to-announce-fourth-quarter-and-full-year-2025-results-6480327)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/EVO
- Earnings history: https://www.quantisnow.com/earnings/EVO
- Dividend history: https://www.quantisnow.com/dividends/EVO
- Insider transactions: https://www.quantisnow.com/insiders/EVO
- Options chain: https://www.quantisnow.com/options/EVO
- SEC 8-K filings only: https://www.quantisnow.com/company/EVO/8-k
- RSS and alerts for EVO: https://www.quantisnow.com/docs/rss-feeds.md
